ON Semiconductor Corp
Change company Symbol lookup
Select an option...
ON ON Semiconductor Corp
KHC Kraft Heinz Co
SUMO Sumo Logic Inc
TPGY+ TPG Pace Beneficial Finance Corp. *W EXP 10/09/2027
CSTA^ Constellation Acquisition Corp I
HFBL Home Federal Bancorp Inc of Louisiana
FSEA First Seacoast Bancorp
GRN iPath? Series B Carbon ETN
HYPMY Hypera SA
WILC G Willi-Food International Ltd
Go

Information Technology : Semiconductors & Semiconductor Equipment | Mid Cap Blend
Company profile

ON Semiconductor Corporation offers a portfolio of sensors, power management, connectivity, custom and system on chip (SoC), analog, logic, timing, and discrete devices. The Company's segments include Power Solutions Group, Analog Solutions Group and Image Sensor Group. The Power Solutions Group offers a range of discrete, module and integrated semiconductor products. The Analog Solutions Group designs and develops analog, mixed-signal and logic application specific integrated circuits (ASICs) and application specific standard products (ASSPs), and power solutions. The Image Sensor Group designs and develops complementary metal oxide semiconductor (CMOS) and charge-coupled device (CCD) image sensors, as well as proximity sensors, image signal processors, and actuator drivers for autofocus and image stabilization for various end users in the automotive, industrial, consumer, wireless, medical, and aerospace/defense markets.

Closing Price
$37.78
Day's Change
0.01 (0.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
38.28
Day's Low
37.50
Volume
(Below Average)
Volume:
4,232,072

10-day average volume:
4,984,001
4,232,072

Senseonics Announces Equity Grants To Employees Under Inducement Plan

7:55 pm ET April 1, 2021 (BusinessWire) Print

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the "Plan") in accordance with NYSE American Company Guide Section 711(a).

On April 1, 2021, Senseonics Compensation Committee granted 5 new non-executive employees non-qualified stock options to purchase an aggregate of 62,000 shares of the Company's common stock as an inducement for such employees to join the Company. The options have an exercise price of $2.58 per share, which was the closing price of the Company's common stock on the NYSE American on April 1, 2021. In each case, 25% of the shares underlying the options will vest on the first anniversary of the employee's start date, with the remainder vesting in monthly installments over the subsequent three year period, in all cases contingent on such employee's continued service with the Company at the applicable vesting date. Senseonics continues to work to bring its Eversense CGM System to more people with diabetes in the U.S. and other markets around the globe and drives to develop enhancements to the system.

About Eversense

The Eversense(R) Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense(R) and Eversense(R) XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005966/en/

SOURCE: Senseonics Holdings, Inc.

Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
investors@senseonics.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.